

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Viginia 22313-1450 www.uspto.gov

APPLICATION NO.	· FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/087,929	03/01/2002	Clarence N. Ahlem	202.8	7989
26551	7590 08/01/2003			
HOLLIS-EDEN PHARMACEUTICALS, INC.			EXAMINER	
4435 EASTGATE MALL SUITE 400			QAZI, SABIHA NAIM	
SAN DIEGO	, CA 92121		ART UNIT	PAPER NUMBER
	, *		1616 DATE MAILED: 08/01/2003	4

Please find below and/or attached an Office communication concerning this application or proceeding.

,		Application No.	Applicant(s)				
,		10/087,929	AHLEM ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Sabiha Qazi	1616				
	The MAILING DATE of this communication app		orrespondence address				
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timety filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status	Decreasive to communication(s) filed on 04 A	Anrah 2002	•				
1)	Responsive to communication(s) filed on <u>01 N</u>						
2a) □	,—	is action is non-final.	accountion as to the morits is				
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Dispositi	on of Claims						
•	4) ☐ Claim(s) <u>1-45</u> is/are pending in the application.						
	4a) Of the above claim(s) is/are withdrawn from consideration.						
,	Claim(s) is/are allowed.						
6)	Claim(s) is/are rejected.						
7)	Claim(s) is/are objected to.						
8) Claim(s) <u>1-45</u> are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.  Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) ☐ All b) ☐ Some * c) ☐ None of:							
1. Certified copies of the priority documents have been received.							
	2. Certified copies of the priority documents have been received in Application No						
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
<ul> <li>a) ☐ The translation of the foreign language provisional application has been received.</li> <li>15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.</li> </ul>							
Attachment(s)							
2) D Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal F	(PTO-413) Paper No(s) Patent Application (PTO-152)				
S Patent and Tr	ademark Office						

Art Unit: 1616

Claims 1-45 are pending.

## Election/Restrictions

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-15, drawn to method of blood cell deficiency, classified in class 514, subclass 169, 170, 172, 178, 179, 180, 182.
- II. Claims 16-19, drawn to compounds of formula V, classified in class 552, subclass (various).
- III Claims 20-24, drawn to compounds of formula VII, classified in class 552, subclass (various).
- IV Claims 25-32, drawn to compounds of formula IX, classified in class 552, subclass (various).
- IV. Claims33-45, drawn to a method of treating symptoms, classified in class 514, subclass 169, 179, 182.

  The inventions are distinct, each from the other because of the following reasons:

Inventions of Group 1, V and II, III and IV are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with

Art Unit: 1616

another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case process for using the product as claimed can be practiced with another materially different product.

Inventions of group I and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions have different mode of operations.

Because these inventions are distinct for the reasons given above, the search required for Group I is not required for Group II to V, and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: See the compounds claimed in claim 31.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species from the elected group for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable. Currently, 1, 16, 20, 25, and 33 are generic.

Art Unit: 1616

A telephone call was made to Attorney Daryl D. Muenchau on 7/31/03 to request an oral election to the above restriction requirement, but did not result in an election being made.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Sabiha

Art Unit: 1616

Qazi whose telephone number is 703-305-3910. The examiner can normally be reached on every business day.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman Page can be reached on 703-308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4556 for regular communications and 703-308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

SABIHA QAZI, PH.D PRIMARY EXAMINER

July 31, 2003